| Identification | Back Directory | [Name]
Oxi 4503 | [CAS]
288847-35-8 | [Synonyms]
CS-1521
AC1OCFKI
Oxi 4503
KB-64255
Rostafuroxine
UNII-JH6Z94GLUD
OXI4503; OXI-4503
Oxi4503|||CA1P|||Oxi4503
CoMbretastatin A1 diphosphate
Combretastatin A-1 bis(phosphate)
Combretastatin A1 diphosphate|||Combretastatin A1 diphosphate
CA1P; 288847-35-8; OXI-4503; AC1OCFKI; UNII-JH6Z94GLUD; COMBRETASTATIN A-1 BIS(PHOSPHATE); KB-64255
1,2-Benzenediol, 3-Methoxy-6-[(1Z)-2-(3,4,5-triMethoxyphenyl)ethenyl]-, 1,2-bis(dihydrogen phosphate) | [Molecular Formula]
C18H22O12P2 | [MDL Number]
MFCD25976806 | [MOL File]
288847-35-8.mol | [Molecular Weight]
492.31 |
| Chemical Properties | Back Directory | [Boiling point ]
766.4±70.0 °C(Predicted) | [density ]
1.529±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
0.99±0.50(Predicted) | [color ]
Off-white to pink |
| Hazard Information | Back Directory | [Uses]
Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors[1][2]. | [in vivo]
Combretastatin A1 phosphate (100 mg/kg; I.p.; once at day 16 post tumor induction) shows anti-tumor activity and exerts anti-angiogenic effects on tumors in mice when combined with Sunitinib (HY-10255A)[2]. | Animal Model: | Male CBA mice (CRC liver metastasis)[2] | | Dosage: | 100 mg/kg (received 40 mg/kg of Sunitinib daily from day 14 to 21 post tumor induction) | | Administration: | I.p.; once at day 16 post tumor induction | | Result: | Demonstrated a significantly decreased mean liver weight compared to livers from non tumor bearing animals, significantly reduced tumor vessels. |
| [References]
[1] Patterson DM, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25. DOI:10.1158/1078-0432.CCR-11-2414
[2] Nguyen L, et al. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. BMC Cancer. 2016 Jul 26;16:533. DOI:10.1186/s12885-016-2568-7 |
|
|